Scientists reprogram cancer cells to fight back against leukemia
NCT ID NCT02483312
Summary
This early-stage study tests whether modifying a patient's own leukemia cells to produce an immune-stimulating protein (IL-12) and returning them to the body is safe. It involves 9 adults with high-risk acute myeloid leukemia who cannot receive bone marrow transplants. Researchers will monitor side effects and track how long the modified cells remain active in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Centre Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.